ArticleCellular and molecular life sciences : CMLS2026
NPY promotes macrophage polarization and hepatic fibrogenesis via PI3K/MAPK-dependent neuroimmune mechanisms.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundNeuropeptide Y (NPY) is a key regulator of neuroimmune homeostasis. However, its role in the intrahepatic immune microenvironment and hepatic fibrosis remains unclear. We aimed to elucidate whether NPY participates in hepatic fibrogenesis via neuroimmune crosstalk and to dissect the underlying molecular mechanisms.
methodsLiver tissues from cirrhotic and non-cirrhotic human subjects were collected. Hepatic fibrosis was induced in mice via intraperitoneal carbon tetrachloride (CCl₄) injection or the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. The distribution of NPY and its receptors was detected in human and mouse hepatic tissues. NPY-knockout mice were used to evaluate the impact of NPY deletion on hepatic fibrosis, inflammation, and macrophage polarization. Hepatic NPY receptors were silenced in vivo, and the corresponding receptors or downstream kinases were blocked in vitro, to define the underlying signaling mechanisms.
resultsNPY was elevated in fibrotic human and mouse livers and primarily secreted by intrahepatic sympathetic nerves. NPY1R and NPY2R (but not NPY4R/NPY5R) were increased and localized in hepatic macrophages. NPY deletion mitigated liver injury, collagen deposition, and inflammation, and suppressed both M1 and M2 macrophage polarization. In vivo knockdown of NPY1R or NPY2R recapitulated these protective effects. In vitro, NPY enhanced M1 polarization via NPY1R/NPY2R-coupled PI3K-PAK1-c-Jun signaling, whereas it promoted M2 polarization through the PI3K-PAK1-RSK cascade.
conclusionNPY drives both M1 and M2 macrophage polarization and accelerates hepatic fibrogenesis through NPY1R/NPY2R-PI3K-MAPK-dependent neuroimmune signaling. These findings identify NPY and its receptors as potential therapeutic targets for hepatic fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.